Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today an ...
The European Commission aims to reduce the EU's heavy reliance on countries such as China and India for antibiotics and other ...
Comparative assessments and other editorial opinions are those of U.S. News and have not been previously reviewed, approved ...
Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...
KOSTAIVE is the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission (EC). KOSTAIVE is currently marketed in Japan against COVID-19. The European Commission approval follows ...
As if sensing an acceleration in pace, last weekend the buzz was focused on London ExCel and the Pokémon European International Championships. Usually held in March, but this year pushed forward ...
The Historic Resources Commission voted to allow a redevelopment and construction plan to move forward for 909 and 913 Tennessee St. in Lawrence. The planned development would replace the parking ...
has received approval from the European Commission. The approval covers major indications of the original drug, including rheumatoid arthritis and giant cell arteritis. Avtozma, an interleukin ...
16d
Korea JoongAng Daily on MSNCelltrion's autoimmune disease treatment gets approval in EuropeCelltrion's Avtozma, a biosimilar to Actemra, was approved by the European Commission for sale in member states.
Mumbai-based Aveo Pharmaceuticals, however, claimed the combination is approved by the relevant state drug authorities and is exported under necessary approval from the assistant drug controllers with ...
BridgeBio Pharma has received European approval for a drug ... share from the blockbuster Pfizer drug that is currently the standard treatment. The European Commission granted marketing ...
Brian Pacheco New York The writer is the managing director of communications for the Drug Policy Alliance. To the Editor: Nicholas Kristof’s column starts with a faulty and harmful premise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results